Videos

Nicholas Silvestri, MD, FAAN, reviews investigational agents and ongoing studies in the pipeline, as well as advice for earlier engagement and evaluation of patients for myasthenia gravis to hasten treatment.

Nicholas Silvestri, MD, FAAN, shares clinical results with eculizumab and ravulizumab, as well as which patients should use biologics and when during the treatment journey.

Nicholas Silvestri, MD, FAAN, discusses neonatal Fc receptor and how it contributes to the pathophysiology of myasthenia gravis, as well as the study design, efficacy, safety, and quality-of-life data with efgartigimod phase 3 ADAPT study.